Neuroscience

#Drug discovery #Neuroscience #Psychedelics

Experienced neuroscientist joins Beckley Psytech as CMO 

Beckley Psytech, a clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has appointed Frank Wiegand as Chief Medical Officer.  Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where… Read More

#News

#Alzheimer's #Drug discovery #Genetics #Life sciences #Neuroscience #Therapeutics

Is new thinking the key to unlocking Alzheimer’s treatment?

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next. Read More

#Editor's Choice #News #Opinion

Seed funding
#Alzheimer's #Clinical trials #Drug discovery #Funding

€9 million to address ‘Agitation/Aggression’ in Alzheimer’s

Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients. This compound is the combination of two clinically validated products,… Read More

#News

Human brain
#Clinical trials #Neuroscience #Pharmacokinetics / Pharmacodynamics

Patients dosed in Phase I trial assessing psychiatric disorders 

Beckley Psytech has dosed the first cohort of volunteers in a clinical trial exploring the safety of its novel formulation of intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT).  The Phase I study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of… Read More

#News

#Neuroscience #Pharmaceuticals

Biotech to develop treatment for neurodegenerative disease 

A team of medical and pharmaceutical experts has founded SynaptixBio, an Oxford-based research company working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting condition. This is a sponsored research agreement with Children’s Hospital of Philadelphia (CHOP) in the US. Read More

#News

#Alzheimer's #Biotechnology #Covid-19 #Research

How has the pandemic impacted Alzheimer’s research? 

Sara Imarisio, Head of Strategic Initiatives at Alzheimer’s Research UK, reveals what dementia research could deliver and how Alzheimer’s research can help us re-imagine a future in which lives are saved.  Alzheimer’s and other forms of dementia have been impacted by Covid-19. With many labs forced to close… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Collaboration #iPSC #Neuroscience

Neuroscience collaboration expands to include novel cell type 

Evotec has expanded its collaboration with Bristol Myers Squibb to include a new cell type.  The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’… Read More

#News

#Biosciences #Neuroscience

Tuning in to the brain’s neural network

The brain: how much don’t we know? Dr Jim Ross, Chief Technology Officer and Co-founder of Axion BioSystems, asks and discusses the answers to this question. Epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s — we hear these brain disease names all the time, but it feels like we never hear about effective treatments or cures. While medical advances are gradually… Read More

#Editor's Choice #Exclusive Content #News

#Alzheimer's #Cancer research #Covid-19

This week in drug discovery (4-8 October) 

News round-up by DDW’s Megan Thomas for 4-8 October  For this week’s drug discovery round up, DDW’s Megan Thomas focuses on stories that provide answers to previously unanswered questions, or news that enables researchers and scientists to find those answers quickly.  1. Novel therapy could… Read More

#News #Trending News

#Clinical research #Parkinson's

New Parkinson’s study investigates treatment of non-motor symptoms  

The design for two new trials investigating opicapone in the treatment of non-motor symptoms in patients with motor fluctuations in Parkinson’s disease (PD) have been presented at the International Parkinson and Movement Disorder Society’s Virtual Congress (MDS Virtual Congress 2021). Usually associated with motor symptoms, opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved in Europe… Read More

#News

#Molecular Biology #Neuroscience #Pharmaceuticals

Novel analgesic drug is based on Nobel prize-winning discoveries 

AlzeCure Pharma says its novel clinical candidate drug ACD440 for peripheral neuropathic pain is based on the seminal discoveries of TRPV1 by Professor David Julius, for which he was awarded the Nobel Prize in Medicine 2021.  Julius, Professor and Chair of the Department of Physiology and Morris Herzstein Chair in Molecular Biology… Read More

#News

#Alzheimer's #Clinical trials #Drug candidates #Drug discovery

First patients dosed in Phase I study for Alzheimer’s

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase… Read More

#News #Trending News

#Alzheimer's

World Alzheimer’s Day 2021: Round up 

The last year has seen virology take the forefront of the drug discovery sector as experts collaborated and worked with unprecedented speed to develop a Covid-19 vaccine to reach an end to the global coronavirus pandemic. But other industries have continued to work tirelessly to develop treatments for other… Read More

#News #Trending News

#Alzheimer's #Brain disease #Drug targets #Schizophrenia

Research reveals drug targets for memory enhancement  

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.  Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

#Drug development #Neurodegenerative disorders #Neuroscience #Parkinson's #Pharmaceuticals

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More

#News